News

Topamax More Effective Than Onfi in Dravet Combo Therapy, Case Report Shows

Topamax (topiramate, TPM) is far more effective than Onfi (clobazam, CLB) when combined with two other medications in reducing the number of seizures in an infant with Dravet syndrome, a Japanese case study shows. The study, “Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient…

FDA to Give GW Pharmaceuticals’ Cannabis-based Therapy for Dravet Syndrome a Priority Review

The U.S. Food and Drug Administration will give priority review to a New Drug Application that GW Pharmaceuticals submitted for its cannabis-based therapy for two difficult-to-treat epilepsies that appear in childhood. U.S. regulators” decision to review the application on an accelerated timetable follows GW’s submission  of a Marketing Authorization Application to…

Breathing Abnormalities May Cause SUDEP in Dravet Patients, Study Says

Sudden unexplained death in epilepsy (SUDEP) in patients with Dravet syndrome can be caused by breathing abnormalities associated with an epileptic seizure, which may slow down the heart rate and eventually lead to death, a study shows.